Synthesis, characterization, and in vitro evaluation of TRAIL-modified, cabazitaxel -loaded polymeric micelles for achieving synergistic anticancer therapy
Authors:
- 10 June 2018
- journal article
- research article
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 29 (14) , 1729-1744
Abstract
Combination therapy of two or more drugs has gradually become of outmost importance in cancer treatment. Cabazitaxel (CTX) is a taxoid drug and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of TNF superfamily. In this study, we prepared TRAIL-modified and CTX-loaded polymer micelle (TRAIL-M-CTX). This nanoparticle was self-assembled from biodegradable amphiphilic copolymers, monomethoxyl poly(ethylene glycol)–b-poly(DL-lactide) (mPEG-PLA) and COOH-PEG-PLA, via a nanoprecipitation method and were modified with the TRAIL protein, resulting in a particle size of 39.75 ± 0.17 nm in diameter and a drug encapsulation efficiency of 95.52 ± 1.69%. The successful coupling was confirmed by 1H NMR, FTIR spectroscopy, and DLS article size measurement. Pharmacodynamic analysis in two human cancer cell lines with different TRAIL sensitivities showed that TRAIL-M-CTX has a significantly better anticancer efficacy than the individual CTX and TRAIL protein. Importantly, TRAIL-M-CTX showed synergistic effects against TRAIL-insensitive cells (MCF-7). A study of cellular uptake implied that the modified micelles were internalized into MCF-7 cells more effectively than unmodified micelles, owing to the coupled TRAIL protein. A cell cycle assay of MCF-7 cells revealed that TRAIL-M-CTX significantly increased the sub-G1 population compared with CTX or TRIAL, thus, facilitating cancer cell apoptosis. These results suggest that TRAIL-M-CTX micelles have potential as a cancer chemotherapy formulation.Keywords
Funding Information
- National Natural Science Foundation of China (81673969)
- Shanghai Leading Academic Discipline Project (Project B505, B505)
- National Special Fund for the State Key Laboratory of Bioreactor Engineering (2060204)
This publication has 34 references indexed in Scilit:
- Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosisOncogene, 2013
- Cabazitaxel-Induced Stabilization of Microtubules Enhances Radiosensitivity in Ovarian Cancer CellsFrontiers in Oncology, 2013
- Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate CancerClinical Medicine Insights: Oncology, 2012
- TRAIL and Paclitaxel Synergize to Kill U87 Cells and U87-Derived Stem-Like Cells in VitroInternational Journal of Molecular Sciences, 2012
- “OA02” Peptide Facilitates the Precise Targeting of Paclitaxel-Loaded Micellar Nanoparticles to Ovarian Cancer In VivoCancer Research, 2012
- Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cellsJournal of Cancer Research and Clinical Oncology, 2012
- Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymersProceedings of the National Academy of Sciences, 2008
- Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactionsAnnals of Allergy, Asthma & Immunology, 2005
- Promoting apoptosis as a strategy for cancer drug discoveryNature Reviews Cancer, 2005
- Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL SensitivityMolecular and Cellular Biology, 2004